All In Biotech

Drug Trial Radar · NCT06161025

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 860 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

860

Planned (sponsor's estimate)

Start

Feb 27, 2024

Primary completion

Feb 29, 2028

Study completion Apr 30, 2030

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Dec 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.

Conditions

  • Solid Cancer

Interventions

  • R-DXdDrug

    R-DXd will be administered as an intravenously (IV) infusion

  • PaclitaxelDrug

    Paclitaxel will be administered as an IV infusion

  • TopotecanDrug

    Topotecan will be administered as an IV infusion

  • PLDDrug

    PLD will be administered as an IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Assessment (Part A)Time frame: From date of randomization to data cut off, up to 18 months
  2. Progression-free Survival (PFS) Based on BICR Assessment (Part B)Time frame: From date of randomization to data cut off, up to 26 months

Locations

167 sites in 19 countries. Site status is shown where the registry gives one.

  • Alaska Women's Cancer Care

    Anchorage, Alaska · Recruiting

  • Yale University School of Medicine

    New Haven, Connecticut · Recruiting

  • Sylvester Comprehensive Cancer Center at Lennar

    Coral Gables, Florida · Active not recruiting

  • Sylvester Comprehensive Cancer Center at Deerfield Beach

    Deerfield Beach, Florida · Active not recruiting

  • Florida Cancer Specialists

    Lake Mary, Florida · Recruiting

  • Sylvester Cancer Center

    Miami, Florida · Recruiting

  • Mount Sinai Comprehensive Cancer Center

    Miami Beach, Florida · Recruiting

  • Sylvester Comprehensive Cancer Center at Plantation

    Plantation, Florida · Active not recruiting

  • Community MD Anderson Cancer Center- East

    Indianapolis, Indiana · Active not recruiting

  • Community MD Anderson Cancer Center- South

    Indianapolis, Indiana · Active not recruiting

  • Community Health Network - MD Anderson

    Indianapolis, Indiana · Recruiting

  • St. Vincent Gynecologic Oncology

    Indianapolis, Indiana · Recruiting

  • St. Elizabeth Medical Center

    Edgewood, Kentucky · Recruiting

  • Baystate Medical Center

    Springfield, Massachusetts · Active not recruiting

  • Washington University School of Medicine Obstetrics and Gynecology

    St Louis, Missouri · Recruiting

  • Valley Health System

    Paramus, New Jersey · Recruiting

  • Holy Name

    Teaneck, New Jersey · Recruiting

  • NHPP Imbert

    Bay Shore, New York · Active not recruiting

  • Northwell Health, LLC PRIME

    Lake Success, New York · Recruiting

  • Perlmutter Cancer Center at NYU Langone Hospital- Long Island

    Mineola, New York · Active not recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • NHPP LHH

    New York, New York · Active not recruiting

  • Novant Health Presbyterian Medical Center

    Charlotte, North Carolina · Recruiting

  • Duke Women's Cancer Care- Raleigh

    Durham, North Carolina · Active not recruiting

  • Duke Cancer Center

    Durham, North Carolina · Active not recruiting

  • Ohio State University Wexner Medical Center

    Hilliard, Ohio · Recruiting

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma · Recruiting

  • Oklahoma Cancer Specialists and Research Institute

    Tulsa, Oklahoma · Recruiting

  • Oncology Associates of Oregon, P.C.

    Eugene, Oregon · Recruiting

  • Perelman School of Medicine at the University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • Medical University of South Carolina (MUSC)

    Charleston, South Carolina · Recruiting

  • Sanford Cancer Center Gynecologic Oncology

    Sioux Falls, South Dakota · Recruiting

  • Texas Oncology-Bedford

    Bedford, Texas · Active not recruiting

  • Houston Area Locations- Woodlands

    Conroe, Texas · Active not recruiting

  • Texas Oncology-Presbyterian Cancer Center Dallas

    Dallas, Texas · Active not recruiting

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center

    Dallas, Texas · Active not recruiting

  • Texas Oncology Paris

    Fort Worth, Texas · Recruiting

  • Houston Methodist Hospital

    Houston, Texas · Recruiting

  • University of Texas - MD Anderson

    Houston, Texas · Recruiting

  • Houston Area Locations- Sugar Land

    Houston, Texas · Active not recruiting

Showing 40 of 167 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.